Diuretics
Frei et al (1994)19 compared monotherapy with moxonidine (0.4mg once-daily) versus hydrochlorothiazide (25mg once-daily) in patients with newly diagnosed or unsatisfactorily controlled mild-to-moderate hypertension in a double-blind, placebo-controlled parallel group, prospectively randomised study in general practice. The intent-to-treat patient sample consisted of 160 patients.
After eight weeks of monotherapy with moxonidine or hydrochlorothiazide there were statistically significant reductions in blood pressure compared with placebo (p<0.05), with no significant differences between the two active treatments. This study also evaluated blood pressure response when using the two active agents in combination with each other; these results are described in the Combination Therapy section. Read more...
Beta-blockers
Prichard, Simmons, Rooks, et al (1992)20 reported that moxonidine was as effective as atenolol in a multicentre, randomised, double-blind, parallel groups study in general practice. A total of 79 patients aged 18-70 years were enrolled; patients were eligible for inclusion if they had mild-to-moderate hypertension with sitting diastolic blood pressure 95-115 mmHg. Read more...
ACE inhibitors
Lotti & Gianrossi (1993)21 reported the results of a randomised, double-blind study comparing four weeks of treatment with moxonidine (0.2-0.4mg daily; n=25) versus the ACE inhibitor captopril (25-50mg daily; n=25). Outpatients aged 20-75 years (mean 57 years) were included in the study if their diastolic blood pressure was 95-115 mmHg when measured after a 1-week washout phase and a 1-week placebo baseline period. Read more...
Calcium-channel blockers
Wolf (1992)26 compared moxonidine with a sustained-release formulation of nifedipine in a multicentre, double-blind, parallel group study. Following a 3-week placebo run-in phase, 229 patients (mean age 56 years, diastolic blood pressure 96-114 mmHg) were randomly allocated to receive 26 weeks of once-daily treatment with moxonidine (0.2mg/day, n=116) or sustained-release nifedipine (20mg/day, n=113). The dose was doubled if diastolic blood pressure remained greater than 90 mmHg after four weeks of treatment. Read more...